Clinical trials: GLP-1
Gastric Cancer, Dumping Syndrome
Gastrectomy, Eating Behaviour and GLP-1
Patients who have undergone gastrectomy (removal of the stomach) to treat or prevent cancer are known to have a significantly reduced quality of life. To date, there is very little information on the physiological causes of this.
- Trial name
- NCT02971631
- Testing
- Exendin 9-39
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
CABG
Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery
This research is being done to see if giving a hormone called GLP-1 can improve heart function and reduce length of stay in the Cardiac Surgical Intensive Care Unit (CSICU) in people who have non-emergent coronary artery bypass…
- Trial name
- GLP-1 CABG (NCT00966654)
- Testing
- GLP-1 (7-36) amide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 1
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes.
- Trial name
- PHROG (NCT04432090)
- Testing
- Study Medication (MBX-2982), No medication for this group
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Diabetes Mellitus
Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas
The investigators hypothesize that our closed-loop glucose-control system can provide BG control in subjects with type 1 diabetes using the estimated BG signal from a CGM as the input signal to the controller.
- Trial name
- CL2 (NCT01161862)
- Testing
- Bi-hormonal (insulin and glucagon) artificial pancreas
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston University Charles River Campus
Overweight or Obesity
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
- Trial name
- FALCON (NCT06854952)
- Testing
- TERN-601
- Where
- 17 sites in United States
- Volunteers
- 167 people
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study.
- Conditions
- Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
- Trial name
- NCT02171130
- Testing
- Nasal Glucagon
- Where
- 9 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 1
A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas
This study will test the hypothesis that a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults with type 1 diabetes.
- Trial name
- NCT02092220
- Testing
- Bionic Pancreas, Insulin pump with or without CGM
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Type2 Diabetes, Kidney Diseases
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
This is a prospective study to evaluate effect of Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
- Trial name
- 1981 (NCT03029351)
- Testing
- Exenatide Extended Release for Inj Susp 2 MG
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University at Buffalo
Diabetes Mellitus, Type 1
The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes
This project focuses on development of new strategy for the prevention of exercise-associated hypoglycemia using mini-dose glucagon.
- Trial name
- NCT02660242
- Testing
- G-Pen Mini™ (glucagon injection), Glucose Tabs, Basal Insulin Reduction
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Jaeb Center for Health Research
Type 1 Diabetes
The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improve glycemic control vs.
- Trial name
- NCT02105324
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 2
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.
- Trial name
- BRIGHT (NCT02738151)
- Testing
- Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
- Where
- 158 sites in United States, Bulgaria and 14 more
- Volunteers
- 929 people
- Sponsor
- Sanofi
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to sulfonylurea without or with metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-S (NCT00713830)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 16 sites in United States, Bulgaria and 14 more
- Volunteers
- 859 people
- Sponsor
- Sanofi
Pre-diabetes, Type 2 Diabetes
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
This study evaluates exenatide, sitagliptin, and glimepiride for the treatment of high blood sugar in patients with impaired fasting glucose or early type 2 diabetes.
- Trial name
- NCT00775684
- Testing
- Exenatide, Sitagliptin, Glimepiride
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Pennsylvania
Healthy
The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
The purpose of this research is to help understand the relative importance of changes in insulin secretion (which lowers glucose) and changes in glucagon (which raises glucose) to regulate metabolism and the body's ability to…
- Trial name
- NCT04461015
- Testing
- 0.4mU Insulin followed by withdrawal period followed by 0.8mU study, 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
Type 2 Diabetes Mellitus
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).
- Trial name
- NCT01584232
- Testing
- LY2189265, Insulin glargine, Sulfonylureas (SU)
- Where
- 15 sites in Japan
- Volunteers
- 361 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Type 2 Diabetes
The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance
The current study is designed to determine the effect on mean glucose, hypoglycemia, glucagon usage, and insulin usage of adjusting upward the glucose target of the bi-hormonal bionic pancreas, and determine whether there is a…
- Trial name
- NCT02509065
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Type 2 Diabetes Mellitus
A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.
As current study is conducted to provide additional information regarding safety and efficacy Bydureon, exenatide once weekly for injectable suspension, in the Korean population open label, non-comparative, multi-centre design is…
- Trial name
- Bydureon (NCT02533453)
- Testing
- Bydureon
- Where
- 15 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- AstraZeneca